People

Zhaohua Chang founded the MicroPort operating business in Shanghai in 1998 and now chairs MicroPort Scientific’s board and serves as chief scientific officer. His earlier medical-device work included Endocare and Cryomedical Sciences. He studied refrigeration and cryogenic engineering and earned a biological-sciences doctorate at SUNY Binghamton.

Qing Hui leads organizational capability at MicroPort Scientific. She joined in July 2019 after human-resources leadership work at Boston Scientific. Her company remit concerns organizational development at headquarters.

Tianbai Yu appears in MicroPort Scientific’s global leadership directory through his subsidiary responsibilities: leading MicroPort Orthopedics China and the orthopedics business’s global supply chain. He joined the group in 2015 and previously led Suzhou MicroPort OrthoRecon operations.

He Li is MicroPort Scientific’s board secretary and leads securities and legal affairs. She joined the group in May 2016. Her operating board-secretary role is distinct from the listed issuer’s separate company-secretary appointment.

Guoming Chen oversees project investment management and technology development at MicroPort Scientific. Since joining in 2010, his work has included valve development, project management and manufacturing processes, including the VitaFlow transcatheter-valve program.

Jie Zhang directs MicroPort Scientific’s Greater China technology function. He joined the company in 2007 and has worked on its medical-device research. His published professional experience includes technical leadership in Shanghai and postgraduate mentorship.

Yimin Xu oversees MicroPort Scientific’s regulatory affairs and infrastructure. His earlier MicroPort responsibilities included quality and regulatory management. He joined the company in 2000 following project-management work at Shanghai Zhangjiang.

Yiyun Que oversees AI manufacturing and the global supply chain at MicroPort Scientific. His earlier company appointments covered coronary-device manufacturing and engineering. The company describes more than twenty years of medical-device experience.

Lei Jiang directs MicroPort Scientific’s Greater China sales and marketing. His career includes pharmaceutical and vascular-device work at Mitsubishi Chemical and Abbott, followed by coronary-device marketing at MicroPort.

Brian Yale Chang is MicroPort Scientific’s chief medical officer and also heads MicroPort Scientific America. He is a physician and engineer whose work includes cardiac-support technologies. His education spans Carnegie Mellon, MIT and Harvard Medical School, with medical residency at Massachusetts General Hospital.

Benoit Clinchamps oversees MicroPort Scientific’s overseas operations. He previously headed the group’s cardiac-rhythm-management business and held medical-technology roles at LivaNova, Sorin and GE Healthcare. His engineering education was at ICAM in France.

Hongbin Sun leads finance at MicroPort Scientific. His earlier work included finance and general management at Otsuka China and accounting at KPMG Shanghai. He studied economics at Shanghai Jiao Tong University and holds Chinese CPA and CFA credentials.

Greg Holman oversees MicroPort Scientific’s global commercial strategy. His earlier career included senior roles at Boston Scientific and Stryker and an operating-partner appointment at LYFE Capital. He earned an MBA at Washington University in St. Louis and an undergraduate degree at Wittenberg University.

Jonathan W Chen leads MicroPort Scientific as rotating chief executive. His earlier MicroPort responsibilities covered overseas operations and investor relations. Before MicroPort, he worked in business development at Angiotech and in life-sciences investment banking. He studied economics and biological sciences at Stanford. This executive is distinct from the Ammobia chemical engineer Jonathan Chen.

Feldan Therapeutics board member and a managing director at Genesys Capital, according to the company’s board biography and September2024 financing announcement. His background includes life-science venture investment and biotechnology board service. Feldan identifies an MBA qualification. Managing director of Genesys Capital. Joined in2002 and became partner in2007. His current manager biography describes board work including Feldan, Enspire DBS Therapy, Giiant and Veralox. Earlier worked in genetic diagnostics at Mount Sinai’s Samuel Lunenfeld Research Institute; holds Queen’s biology and Rotman MBA qualifications.

Board member of Feldan Therapeutics. Her official biography describes extensive drug discovery and development experience and leadership in Canadian biotechnology. Feldan identifies a master’s qualification; the company’s current board directory establishes her affiliation.

Feldan Therapeutics board member appointed in January2025. Previously chief medical officer and global head of development at Allergan, with more than three decades of clinical and non-clinical pharmaceutical-development experience according to the company. Feldan identifies PhD and MD qualifications.

Board member of Feldan Therapeutics with pharmaceutical commercial leadership and consulting experience. Her published company biography describes executive work at Allergan and Kythera and board service in biotechnology. Feldan identifies an MBA qualification.

Chair of Feldan Therapeutics. The company describes his experience leading pharmaceutical development and serving on public and private company boards in several countries. His education includes an analytical-chemistry doctorate and chemistry master’s from the University of Massachusetts Amherst and a research fellowship at EPFL.

Annie Boucher is named by Feldan Therapeutics as CLINICAL TRIAL ASSISTANT. The company directory lists Annie Boucher, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Félix Bégin is named by Feldan Therapeutics as MASTER'S STUDENT. The company directory lists Félix Bégin, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Nayeli Esparza is named by Feldan Therapeutics as POSTDOCTORAL FELLOW. The company directory lists Nayeli Esparza, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Jonathan Roger is named by Feldan Therapeutics as CLINICAL STUDY MANAGER. The company directory lists Jonathan Roger, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Flora Peillard Fiorente is named by Feldan Therapeutics as STRATEGIC DEVELOPMENT SPECIALIST. The company directory lists Flora Peillard Fiorente, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Marie-Michèle Labrecque is named by Feldan Therapeutics as ASSOCIATE CLINICAL STUDY MANAGER. The company directory lists Marie-Michèle Labrecque, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Jean-Pascal Lepetit-Stoffaes is named by Feldan Therapeutics as Director - Strategic Development. The company directory lists Jean-Pascal Lepetit-Stoffaes, PhD, Eng; The current official directory establishes this affiliation; appointment date is undisclosed.

Gaëlle Bourriquen is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Gaëlle Bourriquen, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Alex-Anne Allaire is named by Feldan Therapeutics as COMMUNICATIONS & ADMINISTRATION ASSOCIATE. The company directory lists Alex-Anne Allaire; The current official directory establishes this affiliation; appointment date is undisclosed.

Olympe Garnier--Leymonerie is named by Feldan Therapeutics as PHD STUDENT. The company directory lists Olympe Garnier--Leymonerie, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Alain Houde is named by Feldan Therapeutics as LABORATORY TECHNICIAN. The company directory lists Alain Houde, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Catherine Lippé is named by Feldan Therapeutics as VP - Clinical Development. The company directory lists Catherine Lippé, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Julie Philippe is named by Feldan Therapeutics as ADMINISTRATIVE ASSISTANT. The company directory lists Julie Philippe; The current official directory establishes this affiliation; appointment date is undisclosed.

Mia Pelletier is named by Feldan Therapeutics as PHD STUDENT. The company directory lists Mia Pelletier, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Luis Sorroza is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Luis Sorroza, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Mario Harvey is named by Feldan Therapeutics as SENIOR RESEARCH SPECIALIST. The company directory lists Mario Harvey, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Christine Hurley is named by Feldan Therapeutics as Director - Quality Assurance & Compliance. The company directory lists Christine Hurley, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Maxime Hervault is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Maxime Hervault, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Imen Arbi is named by Feldan Therapeutics as RESEARCH SPECIALIST I. The company directory lists Imen Arbi, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Stéphanie Levesque is named by Feldan Therapeutics as Director - Corporate Governance & Communications. The company directory lists Stéphanie Levesque, BSc, MBA; The current official directory establishes this affiliation; appointment date is undisclosed.

David Guay is named by Feldan Therapeutics as VP - INNOVATION & TECHNOLOGY. The company directory lists David Guay, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Nadine Brahiti is named by Feldan Therapeutics as PROJECT MANAGER - DRUG DELIVERY TECHNOLOGIES. The company directory lists Nadine Brahiti, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Janick Sirois-Fraser is named by Feldan Therapeutics as Financing & Business Development Associate. The company directory lists Janick Sirois-Fraser, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Vincent Ménard is named by Feldan Therapeutics as Chief Financial Officer (CFO). The company directory lists Vincent Ménard, PhD, MBA, CFA; The current official directory establishes this affiliation; appointment date is undisclosed.

Kelly Tanguay is named by Feldan Therapeutics as Research Specialist I. The company directory lists Kelly Tanguay, BSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Vanessa Théberge is named by Feldan Therapeutics as PROJECT MANAGER - DRUG DISCOVERY. The company directory lists Vanessa Théberge, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Pierre-Alain Moisset is named by Feldan Therapeutics as DIRECTOR - DRUG DEVELOPMENT. The company directory lists Pierre-Alain Moisset, PhD, MBA; The current official directory establishes this affiliation; appointment date is undisclosed.

Nancy Messier is named by Feldan Therapeutics as SENIOR VP - DRUG DISCOVERY. The company directory lists Nancy Messier, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Isabelle Deschênes is named by Feldan Therapeutics as Accounting and Logistic Coordinator. The company directory lists Isabelle Deschênes; The current official directory establishes this affiliation; appointment date is undisclosed.

CEO and co-founder of Feldan Therapeutics. His official biography describes co-founding the company while completing a chemical-engineering doctorate and leading its transition from biological-reagent production and distribution to intracellular delivery technology and investigational therapeutics. He is also listed as a Feldan and Bio-Québec board member.

Anne-Marie Duperré is named by Feldan Therapeutics as RESEARCH SPECIALIST III. The company directory lists Anne-Marie Duperré, MSc; The current official directory establishes this affiliation; appointment date is undisclosed.

Meriem Benchabane is named by Feldan Therapeutics as VP - STRATEGIC DEVELOPMENT & OPERATIONS. The company directory lists Meriem Benchabane, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Maud Auger is named by Feldan Therapeutics as RESEARCH SPECIALIST II. The company directory lists Maud Auger, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Al Halifa Soultan is named by Feldan Therapeutics as Director R&D – Drug Delivery Technologies. The company directory lists Al Halifa Soultan, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Anna Xue Cheng is named by Feldan Therapeutics as Director R&D – Pulmonary Drug Delivery. The company directory lists Anna Xue Cheng, PhD; The current official directory establishes this affiliation; appointment date is undisclosed.

Has worked in neurobiology, computational biology and machine learning, and has software-engineering experience at Google and a media startup.

Has worked in startup strategy and operations, led a consulting firm, and worked as an engineer at Microsoft and Bridgewater.

Has experience in circuit design, signal processing and radio communications, including sensor and electronic-warfare work at Raytheon and Lockheed Martin; authored a textbook on radio systems.

Works on ranking models, content quality and language-model demonstrations; previously a senior machine-learning engineer at Booking.com and Yandex. His own experience record dates his Keenable role from January 2026.

Previously a principal applied scientist at Amazon AGI, building web grounding and large-scale retrieval infrastructure.

Previously led Yandex Search and Ads and directed web infrastructure at Amazon AGI.

Neurobiologist and co-founder of Braingaze, leading its eye-movement biomarker technology.

Healthcare leader with life-sciences strategy, consulting, market-expansion and digital-innovation experience at IQVIA, Sensirion and Siemens.

Venture-capital investor in university technology spinouts, previously involved in ApaTech, pharmaceutical business development, Imperial incubation, MTI medical-technology investments and LifeArc seed funding.

Technology and media leader working in commercial transformation, product innovation and growth.

Scientist working in scalable innovation and business transformation, with experience at Costa Coffee and Unilever.

Healthcare executive and investor with experience building R&D teams and launching medicines globally. Annalisa Jenkins is a physician and biotechnology executive advising Automata on clinical development and the growth of life-sciences companies. Previously led Dimension Therapeutics and held biopharmaceutical leadership roles. Her existing RYSE affiliation is preserved; this advisory role is separate from a statutory board or personal investment.

Former worldwide CEO and chairman of Saatchi & Saatchi; the published RYSE role is labelled Leadership without an additional invented corporate title.

Finance professional with investment-banking, private-equity and venture-capital experience; Warwick MBA and Wharton executive fintech education.

Scientist, business-development executive and investor with experience in R&D, medical affairs, pharmaceutical partnerships, medical technology and biotech.

Healthcare investor with more than 25 years of policy and distribution-contract experience, including pharma and biotech research roles at ING and S&P Global.

Founder and technology operator with three startup exits; Cambridge and INSEAD graduate and non-executive director at Techspert.io.

Physician, scientist, engineer and investor; the firm identifies him as a Cambridge University fellow and NHS board member.

Investor and biochemist, formerly a banker at Merrill Lynch, Morgan Stanley and Schroders.

Investment-industry finance and risk-management professional with hedge-fund and real-estate CFO experience; Canadian and US CPA qualifications.

Technology entrepreneur and mental-health company investor and board member; previously co-founded digital platforms including GIA and Fusion.

Founder of the Vision Optimization Summit and filmmaker of My Neuroplastic Adventure, working in psychedelics and health optimization.

Finance and operations professional with more than 25 years at RBC across banking, finance, corporate credit and foreign exchange; CFA charterholder.

Intellectual-property and regulated-health-products lawyer, licensed Ontario pharmacist, and registered Canadian patent and trademark agent.

Previously headed hedge-fund investments at Northwater Capital Management and served as chief investment officer at DGAM and the Carlyle Liquid Markets Group.

Nemariam Mesfin is chief financial officer of Asset Management Ventures, LLC, listed in its March 2026 SEC filing with an appointment beginning September2022. Cedars-Sinai’s own Technology Ventures report separately lists Mesfin as fractional CFO of Cedars-Sinai Health Ventures. Neither source establishes a full-time employment arrangement at AMV.

Richard T. “Rich” Simoni is a managing member of Asset Management Ventures, LLC, confirmed in its March 2026 SEC filing. Its archived own team directory identifies him as Rich Simoni, Partner, and its own current LinkedIn page lists Richard Simoni among employees.

Michael Weintraub is published by Atropos Health as board member. Co-Founder and Managing Partner, Ardan Equity. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Matthew Bettonville is published by Atropos Health as board member. Investor at Yosemite. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Gerald McDougall is published by Atropos Health as life sciences advisory board member. Atropos Health Life Sciences Advisor. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Barbara Salami is published by Atropos Health as life sciences advisory board member. Fmr Vice President, Moderna. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Brian Hasselfeld is published by Atropos Health as clinical advisory board member. Senior Medical Director, Digital Health Innovation, Johns Hopkins Medicine. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

David McSwain is published by Atropos Health as clinical advisory board member. System Chief Medical Informatics Officer & Professor of Pediatric Critical Care Medicine, UNC Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Tip Kim is published by Atropos Health as clinical advisory board member. Chief Market Development Officer, Stanford Health Care. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Elmer Polite is published by Atropos Health as clinical advisory board member. Eastern Division Interim President & Chief Financial Officer, LifePoint Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Rasu Shrestha is published by Atropos Health as clinical advisory board member. Chief Innovation and Commercialization Officer, Executive Vice President, Advocate Health. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Robert Harrington is published by Atropos Health as clinical advisory board member. Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

David Klonoff is published by Atropos Health as clinical advisory board member. Medical Director of the Dorothy L. & James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center Sutter Health & a Clinical Professor of Medicine, UCSF. President of DTS. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Neera Ahuja is published by Atropos Health as clinical advisory board chair. Clinical Advisory Board Chair Division Chief – Hospital Medicine, Medical Director-Pharmacy, Medical Director- General Inpatient Medicine, Clinical Professor Stanford University School of Medicine. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Cecily Harris is published by Atropos Health as legal. Legal. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Neil Sanghavi is published by Atropos Health as president, products & solutions. President, Products & Solutions. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Drew Turitz is published by Atropos Health as chief financial officer. Chief Financial Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Kevin Smith is published by Atropos Health as chief growth officer. Chief Growth Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Cory Wiegert is published by Atropos Health as chief operating officer. Chief Operating Officer. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Saurabh Gombar is published by Atropos Health as chief medical officer and co-founder. Chief Medical Officer & co-Founder of Atropos Health. Adjunct professor of medicine at Stanford School of Medicine Hear from Dr. Gombar. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Brigham Hyde is published by Atropos Health as chief executive officer and co-founder. Chief Executive Officer & co-Founder of Atropos Health Hear from Dr. Hyde. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket. Audere Capital’s own directory names Dr.Brigham Hyde a venture partner. Its career biography describes founding/leadership experience at ConcertAI and SymphonyAI. Current Atropos Health CEO/cofounder and board membership remain separate existing roles; no individual cash investment is inferred.

Nigam Shah is published by Atropos Health as co-founder. Co-Founder of Atropos Health & Chief Data Scientist at Stanford Health Care Hear from Dr. Shah. The affiliation is with the healthcare AI evidence platform at atroposhealth.com; it does not establish a personal investment ticket.

Luis Martinez is Venture Principal at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Nina Shelat is Director of Government Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Morgan Odell is Director of Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Nick Spiller is Managing Director, All Access Fund at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Jamie Serio is Vice President, Ventures at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Bryan Chambers is Co-Founder & President at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Joshua Baer is Founder & CEO at Capital Factory, according to its current official team directory reviewed October 7, 2026.

Security marketing leader with prior roles at Check Point, Cisco, Seemplicity and CyCognito.

AirMDR co-founder who leads security engineering. His published experience spans SIEM, incident detection and response, and security automation.

AirMDR co-founder and CEO with more than two decades of enterprise security and log-management experience, including ArcSight, Sumo Logic and LogicHub.

Published as Jing Wang on Arize AI’s current team page. This is the Arize Forward Deployed Engineer; a different person with the same name exists in Adex.

Published as Jeff Park on Arize AI’s current team page. This is the Arize Senior Software Engineer; a different person with the same name exists in Adex.

Published as Jim Groff on Arize AI’s current team page. This is the Arize Compliance Officer; a different person with the same name exists in Adex.

Published as Kunal Shah on Arize AI’s current team page. This is the Arize Staff Software Engineer; a different person with the same name exists in Adex.

Luisa Wasilewski is a digital-health entrepreneur, investor, author and adviser. Andrej Steinberg’s original2023 Loop Ventures launch announcement identifies her as a venture partner. Her own current Pulsewave speaker biography identifies her as founder and CEO of Pulsewave and Future Health Academy, adviser to digital-health startups, a board member of Bitkom’s e-health working group and a member of DMEA2026 program leadership working on innovation, startups andAI. Earlier experience includes leading BrainwaveHub for more than fiveyears, building healthcare business models at HeartbeatLabs and consulting at Capgemini. Her Loop affiliation is explicitly qualified as publicly announced in2023 because a complete current fund roster is unavailable. Her authentic portrait is published on her own Pulsewave speaker page.

Bérénice Magistretti is a Swiss-Italian investor, writer and disability-accessibility advocate based in London. Her own biography describes her as a founding partner of Loop Ventures, an early-stage health and biotechnology fund, and her2023 launch announcement identifies Michael Ströck and Andrej Steinberg as co-founders. She previously covered Silicon Valley venture investment for VentureBeat and wrote for TechCrunch, WIRED UK, Vanity Fair and Forbes. Her publicly described work includes advocating for people with invisible disabilities and helping make startup ecosystems more accessible. The current loop.vc website does not publish a complete group roster, so her founding status is retained without claiming confirmed current employment. The original black-and-white portrait is from her own named About page.

Andrej Steinberg is an early-stage technology and healthcare investor based in Berlin and a co-founder of Loop Ventures. His own2023 launch announcement identifies partners Michael Ströck and Bérénice Magistretti and a thesis focused on software for healthcare providers, payers and biopharma. Loop’s own September2026 website identifies Andrej as its lead contact, investing at inception and before, and presents selected investments across agenticAI, healthcare, biotechnology and enterprise software. In his earlier self-written2022 Auxilia article, he described his Calm/Storm Ventures investing role and gave founders advice on capital raising. That earlier role is historical; generic investor directories retaining it do not establish his current employer. The exact named NFX portrait is an authentic120px mirrored investor photograph; its original former-firm page is no longer accessible.

Electrical and computer engineering researcher, also published as Ali Yanik. UC Santa Cruz's own health and wellbeing research directory identifies him as an associate professor. NIH's2025 Redwood Neuro project identifies him as a co-principal investigator on ultrasensitive Alzheimer's biomarker research. This is a sourced research collaboration rather than an asserted executive or full-time corporate appointment.

Biophysics and computational-biology researcher and educator. Santa Clara University's own faculty biography describes a PhD from the University of Illinois Urbana-Champaign, research in bioengineering, medical imaging and data science, and diagnostic-technology entrepreneurship. NIH's2025 Redwood Neuro award identifies him as contact principal investigator; no Redwood CEO or founder title is inferred.

Colin Foster was identified as president of The Next Practices Group in its founder-authored2020 launch. His current biography identifies him as cofounder of The Next Practice agency, which joined Attivo in2025. His work connects brand, data and AI, including Accru iQ clinical-trial recruitment; previously social-media leadership at Novartis and Real Chemistry/W2O. Current NPG parent executive tenure is unverified.

Robert (Bob) V. Lardon was appointed chief strategy officer of The Next Practices Group inOctober2023, supporting network founders and business strategy. Previously strategy and investor relations at HARMAN, strategy leadership at Porter Novelli, and PwC shareholder-value consultancy leadership. His work includes artificial intelligence and immersive technologies. Current NPG tenure is unverified.

Michael (Mike) Gehb is a finance and operations executive and cofounder of The Next Practices Group. Its October2023 announcement names him founder and COO; his own contemporaneous colleague also names him CFO/COO. His current Symbionic Labs biography names him CFO and head of operations and confirms prior NPG cofounding. Previously finance leadership at Omnicom, Porter Novelli and Copithorne & Bellows; CPA. NPG employment end date is unknown.

Bob Pearson founded and chaired The Next Practices Group, most recently confirmed by a2025 Healthcare Businesswomen’s Association biography. He has worked in healthcare and corporate communications at Dell, Novartis and Rhone-Poulenc Rorer, and helped develop GCI Health and Real Chemistry. A communications author and advisor working on AI adoption; current NPG executive roster remains unverified.

Dushyant Chipalkatty is a director of Promaxo Holdings, Inc., as disclosed in its March 2026 SEC filing. His published Otomagnetics scientific-adviser biography describes founding PACK Pharmaceuticals in 2005 and earlier pharmaceutical operating and business-development experience at Morton Grove Pharmaceuticals and Carter-Wallace. He holds pharmacy degrees from Nagpur University and a master’s degree in pharmaceutical sciences from Rutgers. This pharmaceutical executive is distinct from similarly named robotics founders.

Alex Gonzalez is published by Promaxo as Senior Vice President in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Anil Dhingra is published by Promaxo as Executive Vice President in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Scott King is published by Promaxo as Chief Product Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Ram Narayanan is published by Promaxo as Chief Technology Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Alek Nacev is published by Promaxo as Chief Science Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Srirama Venkataraman is published by Promaxo as Chief Operating Officer in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Michael Bartholomew is published by Promaxo as Secretary of the Board in its current company leadership directory. This affiliation concerns its portable MRI and image-guided medical technology business.

Investor at Emergence Capital; previously worked at Qatalyst Partners and studied Computer Science at UCLA.

Kojo Osei is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Lauren Maymar is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Kush Gupta is explicitly listed among US Tau Ventures' Investor Alumni. This is a historical affiliation rather than a claim of current employment; exact service dates are not published.

Sonal Panda is publicly listed as an advisory partner of US Tau Ventures. This advisory affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Ravi Varma, also identified in the firm's January 2026 newsletter as Ravi Varma Namboori, is a publicly listed venture partner of US Tau Ventures. The firm's own portrait and linked professional profile establish the same individual.

Larry Augustin is publicly listed as a venture partner of US Tau Ventures. This affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Gary Ang is publicly listed as a venture partner of US Tau Ventures. This affiliation is distinguished from the firm's core investment staff; appointment dates are not disclosed.

Sharon Huang invests at US Tau Ventures. She previously worked on pharmaceutical strategy at Novartis and software for protein and genomic sequencing at Chan Zuckerberg Biohub. She studied computer science and epidemiology at Stanford and is continuing medical training at Mount Sinai. The current team page publishes Principal; the January 2026 newsletter calls her Vice President, without an assumed promotion date.

Insoo Chang invests in enterprise AI and financial technology at US Tau Ventures. Previously a senior vice president on Citigroup's strategic investment team, he co-founded the AI research-information platform NotedSource. He holds a Harvard MBA and Cornell economics degree. The current team page publishes Principal; the January 2026 newsletter calls him Vice President, with the discrepancy explicitly retained.

Sam Bogrov invests in digital health at US Tau Ventures. Previously he led financial operations at Pediatric Associates and worked in private equity at Investindustrial and Platinum Equity. He holds a Wharton MBA focused on healthcare management, a Vanderbilt bachelor's degree and a Claremont McKenna finance master's. The current team page publishes Principal; the January 2026 newsletter calls him Vice President, a source discrepancy retained rather than an assumed promotion date.

Sanjay Rao co-founded US Tau Ventures and focuses on enterprise software and automation. Previously he worked at Microsoft, McKinsey and Norwest and co-founded an automation startup. He holds MIT electrical engineering and computer science degrees and a Harvard MBA.

Amit Garg co-founded US Tau Ventures in 2019 and focuses on digital health and selected automation investments. His prior experience includes Google, Samsung NEXT and Norwest. He studied computer science and biomedical informatics at Stanford and earned an MBA at Harvard.

Mia Nuñez is NOCD’s director of clinical integrity and director of continuing education. She helps select and assess new therapists, develops professional training and monitors treatment delivery and outcomes as part of its clinical leadership team.

Taylor Newendorp is NOCD’s network director of clinical training. A licensed clinical professional counselor, he oversees training for new and established therapists, including foundational exposure and response prevention instruction and advanced continuing education. He authored The Perfectionism Workbook.

Nicholas Farrell is NOCD’s director of clinical development and programming. He oversees the range of clinical services available through its therapist network and develops training and mentoring for clinicians treating OCD and related conditions.

Tracie Zinman-Ibrahim is NOCD’s chief compliance officer. She oversees risk and compliance policies, clinical auditing and therapist screening while also providing therapy in states where she is licensed. Her own experience receiving exposure and response prevention therapy informs her work treating OCD.

Ilyas Patanam is a co-founder and chief growth officer of NOCD. He helped build its patient community and focuses on member-first growth, increasing understanding of OCD and connecting people with specialist treatment.

Anil Vaitla is a co-founder and chief technology officer of NOCD. He helped develop the company’s early patient community and now works on technology supporting member education, therapy-session experiences, billing and other components of specialist OCD care.

John Jurich is NOCD’s sales and chief revenue officer. He works on expanding access to specialist OCD care through payer coverage and commercial relationships, supporting the company’s technology-enabled clinical delivery model.

Erin Henkel is NOCD’s chief design officer. Her career spans healthcare and design, and her work focuses on creating a welcoming, accessible patient experience across NOCD’s digital services and treatment interactions.

Patrick McGrath is NOCD’s chief clinical officer. A licensed clinical psychologist with decades of OCD treatment experience, he oversees clinical protocols, therapist selection and training, and consultation on complex cases. He is the author of The OCD Answer Book and Don’t Try Harder, Try Different.

Jamie Feusner is NOCD’s chief medical officer, overseeing clinical outcomes, treatment development, research and payer and clinical partnerships. A psychiatrist and OCD researcher, he is also a University of Toronto psychiatry professor and senior scientist at the Centre for Addiction and Mental Health.

Matt Thorne is chief financial officer of NOCD. His career has focused on the role of telehealth technology in healthcare. At NOCD, he supports a business delivering specialist treatment for obsessive-compulsive disorder through a combination of clinical care, technology and patient support.

Chris Novak is NOCD’s chief network operating officer. He focuses on expanding access to specialist OCD care and supporting the therapist network, including clinical training and the experience of therapists serving patients across urban and rural communities.

Larry Trusky is a co-founder and president of NOCD. His career spans healthcare technology, and he joined the founding team after its first patient-community product was developed. His work supports building technology and operations around direct patient care for people with obsessive-compulsive disorder.

Stephen Smith is a co-founder and chief executive officer of NOCD. His experience seeking specialist care for obsessive-compulsive disorder inspired the company’s development. He began designing the idea in 2014, developed its app and patient community, and completed his degree at Pomona College.

Stanford computer-science graduate; previously an AI investor at Bridgewater.

Previously an engineer at Neeva working on indexing, retrieval and language modeling, and a neuroscience researcher studying learning and epilepsy.

Joined as general partner in January 2025; previously an engineering and product executive at Meta and investor at Sequoia.

Jenny Ismert is an executive advisor to Valtruis and an independent healthcare consultant with more than two decades of Medicaid and Medicare experience. Before 2026 she held UnitedHealthcare executive roles in policy, innovation, technology and planning, most recently leading its Kansas Community Health Plan. She studied biology at the University of North Texas and earned an MBA in healthcare services from the University of Colorado.

Sam Deshpande is an executive advisor to Valtruis with over 30 years of experience in healthcare, consumer banking and consulting. He previously served as Humana chief information officer and chief risk officer, leading cloud, AI and data technology adoption. Earlier roles included Capital One, Accenture and Booz Allen Hamilton. His education includes an MBA from the University of Chicago and aerospace engineering degrees from Virginia Tech and IIT Kharagpur.

Paul Jansen is an Executive Advisor at Valtruis specializing in healthcare data and analytics, with extensive experience building and leading analytics teams that deliver actionable insights at scale. He is also a Co-Founder and Principal Consultant at Z2 Health Insights, a healthcare data and analytics consulting practice. Most recently, Paul led analytics at Tuva Health, developing analytics products on a widely adopted open-source healthcare analytics framework. Prior to that, he led value-based care analytics at Teladoc Health and built analytics functions at Bright Health, supporting Individual Marketplace and Medicare Advantage populations across multiple states. Earlier in his career, he held roles at Blue Cross and Blue Shield of Minnesota, the Minnesota Department of Health, and the Navy and Marine Corps Public Health Center. Paul holds a bachelor’s degree in Human Biology from Michigan State University and a Master of Public Health in Epidemiology from the University of Minnesota.

Dave Esler serves as an advisor to Valtruis specializing in human capital strategy, bringing more than 30 years of experience in Human Resource leadership roles across a range of industry sectors. Most recently, Dave served as Chief Administrative and Chief Human Resources Officer at Nashville-based Envision Healthcare. While with Envision, Dave was at the center of a transformative period of M&A activity that brought together a diverse group of healthcare services businesses that offer unique value propositions to clinicians, health systems, and payors. Prior to joining Envision, Dave served for eight years as Chief Human Resources Officer for Illinois-based US FoodsR, supporting more than 26,000 employees. Dave holds a master’s degree in Industrial and Labor Relations from the University of Wisconsin-Milwaukee, completed the Human Resource Executive Program at the University of Michigan, and has been designated a Certified Employee Benefits Specialist (CEBS) by the International Foundation of Employee Benefit Plans. Dave also earned a Bachelor of Science degree in Economics from the University of Wisconsin Oshkosh.

Andy Wong is a healthcare growth executive and operator with more than two decades of experience building, scaling, and transforming consumer and healthcare businesses. He has served in Chief Marketing Officer and Chief Growth Officer roles across high-growth healthcare organizations, with expertise spanning virtual and in-person care delivery, value-based care, women’s health, and employer and health plan markets. Andy has held leadership roles at some of healthcare’s leading consumer and technology-enabled companies, including Galileo, Herself Health, PlushCare, and Accolade. Across these organizations, he has built and led teams across growth, marketing, product management, and commercial strategy.  His track record includes scaling both direct-to-consumer and enterprise healthcare models while building differentiated brands that drive clinical outcomes and sustainable economics. Earlier in his career, Andy held roles at Procter & Gamble, The Boston Consulting Group, The Daily Beast, and Flywheel Sports. Andy holds an MBA from the University of Chicago Booth School of Business and a BA from the University of Michigan, Ann Arbor.

Sarah is a Director of Finance and Administration at Valtruis. Before joining Valtruis, Sarah served as Manager of Corporate Accounting at American Industrial Partners and has nearly a decade of experience spanning private equity, asset management, and financial services. Sarah holds a Bachelor of Science in Accountancy with a Minor in Economics from DePaul University and studied international business at Corvinus University in Budapest.

Miriam de Leon Diaz is Executive Assistant at Valtruis and coordinates logistics, communications and operations for the company’s leadership team. With more than a decade of experience in the healthcare and financial sectors, Miriam has served in administrative positions at OneOncology and CVS Health as well as J.P. Morgan Chase. Certified in Executive Administration, she is bilingual (Spanish) and has won awards for employee excellence at multiple companies. The Valtruis executive team is doing what they truly believe. They’re not just doing this as a ‘job.’ They are going to help make a change in healthcare, and things are going to get better. I admire that, and I'm proud to be a part of it. © 2026 Valtruis Companies | Team | News | Contact

Tracy Bahl is a Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2021 focusing on healthcare investments. He was formerly the President and Chief Executive Officer of OneOncology, a company dedicated to serving all those living with cancer through a network of leading community oncology practices across the U.S. Prior to OneOncology, Tracy served as Executive Vice President of Health Plans for CVS Health; Executive Chairman of Emdeon, an industry leading healthcare information and transaction services company; Special Advisor at General Atlantic; Chief Executive Officer of Uniprise, a UnitedHealth Group Company; and held various executive positions at CIGNA HealthCare. Tracy earned MBA degrees from Columbia University and the London Business School as well as a Bachelor of Arts degree from Gustavus Adolphus College. Tracy Bahl is publicly named in Despierta’s combined advisors and select limited partners roster. The source does not distinguish this individual’s advisory or LP capacity, identify a commitment amount, or supply a substantive biography; its generic image and placeholder biography are excluded. The affiliation is recorded with this explicit limitation.

Manav Sarkaria is a Vice President at Valtruis. Prior to joining the Valtruis team, Manav worked at private equity firm Clayton Dubilier & Rice, where he focused on investments in the healthcare sector. Earlier, he began his career as an Investment Banking Analyst at Morgan Stanley in the Mergers & Acquisitions Group. Manav holds a Bachelor of Science in Finance from Miami University.

Kathy Greer is a Director of Strategic Partnerships at Valtruis. Prior to joining, Kathy was an investor at Cerity Partners Ventures (formerly Touchdown Ventures), where she focused on healthcare venture investing in partnership with Fortune 500 companies. Earlier, she was a management consultant at ZS Associates and began her career at a healthcare technology startup. Kathy holds a Bachelor of Arts in Economics from the University of Michigan.

Karey Witty is Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2020 focusing on healthcare investments. He has over 30 years of experience across a range of senior executive roles in the healthcare industry. Prior to joining WCAS, Karey was the Chief Operating Officer at Envision Healthcare. Prior to Envision Healthcare, he has served as the CEO of Corizon Health Inc., EVP and CFO of naviHealth (a former WCAS XI portfolio company), CFO of HealthSpring, CFO of Valitas Health Services, and CFO of Centene Corp. Karey served as Chief Executive - Health Plan Business Unit at Centene after his time as CFO. Karey earned his Bachelor’s degree from Middle Tennessee State University.

Jess Bossmann is a Vice President at Valtruis. Prior to joining, Jess worked at private equity funds GTCR and Chicago Pacific Founders, where she focused on investments in the healthcare sector. Earlier, she worked in the Diversified Industrials Investment Banking group at J.P. Morgan. Jess holds a Bachelor of Business Administration in Finance from the University of Wisconsin-Madison.

Jack Tillotson is an Associate at Valtruis. Before joining Valtruis, Jack held a role in strategy and business development at agilon health, where he focused on fostering long-term partnerships with independent physician groups and health systems. Prior to that, he began his career at HealthScape Advisors, a management consulting firm, where he helped health plans, provider organizations, specialty health organizations, and investors navigate the evolving healthcare landscape. Jack earned his Bachelor of Business Administration in Accounting and Information Systems from the University of Wisconsin-Madison.

Isaac Ableman is an Associate at Valtruis. Prior to joining, Isaac worked at Baird Capital, where he focused on early stage and growth investments in the technology sector. Prior to that, he worked in the Industrials Investment Banking group at BMO Capital Markets. Isaac holds a Bachelor of Business Administration in Accounting and Finance from Ohio University’s Honors Business College.

Erin Murphy is an Executive Assistant at Valtruis, where she strives for operational excellence and executive success. Prior to joining Valtruis, Erin worked at various technology companies, including Platform Science, a telematics & fleet management company, and Pegasystems, a global CRM & BPM software company. Erin worked in various administrative roles during her time with Pegasystems and supported the Chief Executive Officer, Chief Financial Officer, and Chief Strategy Officer at Platform Science.

Corey Lenhoff is a Vice President at Valtruis. Corey brings experience as both a healthcare startup operator and management consultant; he joined the firm in 2021. Most recently, Corey worked at Pager, a digital health startup focused on care navigation, where he was responsible for strategic initiatives, partnerships and business development. He began his career at HealthScape Advisors, a management consulting firm dedicated to helping health plans, provider organizations, specialty health organizations and investors navigate the healthcare industry. Corey earned his Bachelor's degree from the University of Illinois Urbana-Champaign.

Claire McGee Sharma is an Associate at Valtruis, supporting Platform & Operations. Previously, Claire worked as an Innovation Consulting Associate at Healthbox and a Business Strategy Specialist at HIMSS. Prior to this, she held internship positions at Ohio Innovation Fund, a midwest venture capital fund, and Ariadne Labs, a joint center for health systems innovation at Brigham and Women's Hospital and the Harvard T.H. Chan School of Public Health. She is a Stanford University Innovation Fellow and is passionate about the potential for design thinking and technology to drive improvements in health care delivery. Claire Graduated Summa Cum Laude from Ohio University with a BS in Public Health and a BA in Spanish.

Callie Patel is Senior Vice President of Platform & Operations at Valtruis, bringing more than 10 years of experience partnering with healthcare stakeholders to drive positive transformation. Before joining the Valtruis team, she was a Director at Healthbox, a healthcare advisory firm that leading organizations trust with innovation, commercialization and digital strategy. Callie led engagements across Healthbox's consulting services, including overseeing all engagements focused on the drivers of health/health equity as well as the flagship Foundry Program, cultivating and assessing the viability, enterprise impact, and commercial potential of care team member-led new products and services. Prior to Healthbox, Callie managed healthcare engagements at Huron Consulting Group, spanning community-based hospitals, children's hospitals, academic medical centers, and regional/national delivery systems. Her focus comprised operational excellence, clinical transformation, technology implementations and change management. Callie holds a Bachelor of Science degree in Industrial and Systems Engineering from University of Wisconsin-Madison as well as an MBA from University of Chicago Booth School of Business.

Bo Shi is a Principal at Valtruis. Bo has over 10 years of experience partnering with entrepreneurs and executives in the technology, healthcare, and insurance industries. Most recently, Bo was a Vice President at the Blue Venture Fund and Sandbox Industries where he served on the board of directors for Abacus Insights, Alacura, and Ideal Option. Additionally, he was a board observer for Anzen, Care Connectors, Drips, First Dollar (acquired by Inspira Financial), HealthEdge, Limber Health (acquired by Net Health), and Solera Health. Earlier, Bo was an investor at Waud Capital Partners and Primus Capital, executing growth equity and buyout transactions for vertical software and healthcare companies. He began his career at L.E.K. Consulting. Bo earned his MBA with Honors from the University of Chicago Booth School of Business and his Bachelor of Arts in Economics from the University of Chicago.

Anna Haghgooie is a Managing Director of Valtruis and an Operating Partner at WCAS, having joined in 2021. Anna has over 15 years of experience partnering with entrepreneurs and operators to drive innovation in healthcare. Most recently, Anna was a Managing Director of the Blue Venture Fund and Sandbox Industries. She has previously served on the board of directors of Quilted Health, Somatus, ZeOmega, Contessa, Axial Healthcare, Origin, SonarMD, PWN Health, ExactCare, naviHealth (a WCAS XI former portfolio company), and Change Healthcare. Anna earned her MBA from the Booth School of Business at the University of Chicago and a Bachelor’s degree from the University of Michigan.

Anika Satish is an Associate at Valtruis. Prior to joining the team, she worked at Boston Consulting Group, where she focused on healthcare strategy across pharma, value-based care providers, and medtech. Anika holds a Bachelor of Science in Mechanical Engineering with a minor in Business from the University of Michigan.

Brian Anderson is published by Autonomize AI as Advisory Board Member. Physician and responsible-healthcare-AI leader, identified at appointment as CEO and co-founder of the Coalition for Health AI. His work spans healthcare interoperability, national health-technology policy and consensus frameworks for AI safety, validation and effectiveness.

Bill Fandrich is published by Autonomize AI as Advisory Board Member. Healthcare and financial-services executive with four decades of published experience in enterprise transformation, operations, analytics and artificial intelligence. Advises on scaling AI-enabled operating models and business modernization.

Keith Reynolds is published by Autonomize AI as Advisory Board Member. Digital-health and payer-industry executive, described at appointment as Welldoc ChiefOperatingOfficer and a former CVSHealth executive. Brings experience commercializing AI-enabled healthcare solutions and payer innovation to Autonomize’s advisory board.

Pritesh Gandhi is published by Autonomize AI as Medical Advisor. Physician and public-health-qualified medical adviser published in the current directory and the2025 advisory-board announcement. This is an expert advisory affiliation rather than employment as company ChiefMedicalOfficer or an inferred personal investment.

Anthony Alvarez is Advisor at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Michele Paige is published by Autonomize AI as Advisor, Growth Advisory Board. Pharmacy-benefit-management and pharmacy-operations leader with earlier ElevanceHealth CarelonRx product and digital-strategy experience, including specialty-pharmacy and affordability initiatives. Advises Autonomize growth and pharmacy-linked AI workflows.

Tamara Elias is published by Autonomize AI as Advisor, Growth Advisory Board. Physician executive and former private-equity partner with nearly a decade of investing experience. Published earlier operating and partnership roles span Microsoft/Nuance, Merck, Aetna, BectonDickinson and McKinsey; advises growth across healthcare delivery, pharma and enterprise technology.

Anthony Nguyen is published by Autonomize AI as Chair, Medical Advisory Board (adviser-directory affiliation). Physician and MBA-qualified MedicalAdvisoryBoard chair in the current advisory directory. Its caption additionally says ChiefMedicalOfficer, but SandhyaGardner’s explicitApril23,2026 appointment establishes the current executiveCMO; that potentially older advisor caption is retained only as a source-qualified attribution, not a second asserted executive appointment.

Joan Harvey is published by Autonomize AI as Chair, Growth Advisory Board. Chairs Autonomize’s GrowthAdvisoryBoard, which convenes healthcare industry leaders to guide enterprise expansion and strategic partnerships. This advisory role is distinct from a company board-director appointment and a personal investment ticket.

Mike Longacre is published by Autonomize AI as Head of Transformation. Healthcare transformation executive with more than20 years leading modernization across health plans, pharmacy benefit managers and technology companies. Previously a partner in PwC’s HealthTransformation practice, with earlier ConnectureDRX and UnitedHealthcare leadership; supports enterprise adoption, governance and operating-model change.

Shiv Mallya is Head of Delivery at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Prajna Kandarpa is Chief Architect at Autonomize AI, an Austin-based enterprise healthcare software company developing specialized AI agents and orchestration tools for clinical and operational workflows.

Co-founder and current co-CEO; Fred Hutchinson Cancer Center chief data officer and RNA informatics researcher. Academic title is distinct from his company role.

Also published as Rob Bradley in the issuer’s financing release and Madrona announcement. Fred Hutchinson Cancer Center researcher and translational data science leader; academic position is distinct from his Synthesize co-CEO role.

Caltech faculty scientist whose laboratory developed the DaX peptide-design platform from which Aizen spun out.

University of Utah School of Medicine scientist and D-peptide therapeutics specialist, independently identified by Madrona’s Aizen investment announcement.

Published board advisor, distinct from a board director or employee.

Published as observer in Aizen’s Board Members section, not a voting director or employee.

Gina Collins is published by Autonomize AI as Chief Regulatory Officer. Healthcare regulatory and operational executive with more than20 years of experience. Former office director at FDA’s Center for Devices and Radiological Health and earlier Cigna operational, risk and compliance leader; directs Autonomize regulatory strategy, compliance and enterprise risk management.

Jennifer Rouse is published by Autonomize AI as VP Marketing. Healthcare marketing executive with more than20 years of B2B experience. Former worldwide healthcare-marketing leader at AWS, with earlier IBM, Cisco and Forrester leadership/advisory work across cloud, cybersecurity, compliance and enterprise AI.

Ujjwal Rajbhandari is published by Autonomize AI as VP Solutions & Delivery Engineering. AI-infrastructure and cloud-strategy executive with earlier Google and Dell leadership. Previously a startup co-founder and CTO developing hybrid-cloud GPU-as-a-Service infrastructure. September2025 appointment was Head of Solutions; current directory title is VP Solutions and DeliveryEngineering, whose exact promotion date is undisclosed.

Scott Brennan is published by Autonomize AI as Head of Growth. Healthcare growth executive with more than15 years of go-to-market experience. Previously SVP of BusinessDevelopment at TurningPointHealthcareSolutions, supporting value-based musculoskeletal and cardiovascular care arrangements, and helped scale an earlier healthcare company through acquisition.

Sophia Onat is publicly identified as an ATX Venture Partners team member by the firm founder’s welcome announcement and her own professional profile. A specific current job title and individual manager-published portrait have not been verified.

Peter Kirby is a venture partner at ATX Venture Partners. His published biography describes early Bitcoin hardware and blockchain-company entrepreneurship, including Factom, and biochemistry and business study.

David Godwin is a venture partner at ATX Venture Partners. His manager biography describes technology entrepreneurship and cofounding Slingshot Aerospace; an older external CEO title is not asserted as a verified current appointment.

Jeff Gray is a venture partner at ATX Venture Partners. His published biography describes infrastructure, cloud and cybersecurity leadership and technology consulting.

Michael Flory is a venture partner at ATX Venture Partners. His published biography describes consulting and investment activity through MRFH, and prior operating experience at Rovia and CarTrawler.

Tony Capasso is a venture partner at ATX Venture Partners. His published biography describes revenue leadership at YouEarnedIt/HighGround, ShipEngine, Bazaarvoice and Civitas Learning; these are career references rather than independently verified current outside appointments.

Sandhya Gardner is published by Autonomize AI as Chief Medical Officer. Board-certified obstetrician-gynecologist and ACOG fellow with more than25 years spanning clinical practice and healthcare technology. Earlier HealthEdge ClinicalSaaS GeneralManager/CMO, Wellframe CMO and Relias/AdvancedPracticeStrategies leadership. Leads clinical strategy, AI validation and safety, and enterprise adoption.

Dave Ritter is a venture partner at ATX Venture Partners. His published biography describes former McKinsey partnership and U.S. Army leadership experience and operations-research study.

Laksh Krishnamurthy is published by Autonomize AI as CTO. Technology executive with more than thirty years of experience in platform engineering, AI and advanced analytics. Earlier leadership at Tecnotree and CognitiveScale and technical work at IBM; the firm describes him as an IBM Master Inventor with55 patent filings and an operations-research/computer-applications master’s degree.

Spencer Lucas is chief financial officer of ATX Venture Partners, as published in the current own directory. No expanded biography is published in his current website panel.

Kris Nair is published by Autonomize AI as COO & Co-Founder. Co-founder of Autonomize in2022 with Ganesh Padmanabhan. As COO he represents the company’s operational development of healthcare intelligence and agentic workflows, including its2026 claims payment-integrity application. The native directory does not disclose an extended earlier career biography.

Emerson Miller is a principal at ATX Venture Partners. His manager biography describes entrepreneurial, racing-business operating and technical data-analysis experience. The firm announced his promotion effective January1,2026.

Ganesh Padmanabhan is published by Autonomize AI as CEO & Co-Founder. Enterprise AI and cloud executive with more than twenty years of experience. Former Dell Technologies executive who co-founded Autonomize with Kris Nair in2022 to build governed AI-native healthcare workflows.

Kevin Fiur is a partner at ATX Venture Partners. His manager biography describes operating, legal and transaction experience at iFLY and Baker Botts, with degrees from the University of Texas at Austin and Acton School of Business.

Danielle Allen, also legally Danielle Weiss Allen, is a partner and cofounder of ATX Venture Partners and head of ATX Global Co-Invest. Her manager biography describes institutional finance experience at JPMorgan, Nomura and Millennium; she attended Tulane and earned an MBA from Zicklin.

Julian Spears is Head of Neurosurgery at St. Michael’s Hospital, Unity Health Toronto. Hyperfine named this clinician to its Neurosurgery Advisory Council on June 22, 2026 to advise on portable MRI surgical workflows, product development and clinical evidence. This is an advisory affiliation, distinct from employment.